TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

REGN-COV2 SUPPLY AGREEMENT FOR PANDEMIC PURPOSES

Pharmaceutical products
Wales (UKL)
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Business Energy and Industrial Strategy: "REGN-COV2 SUPPLY AGREEMENT FOR PANDEMIC PURPOSES". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityBusiness Energy and Industrial StrategyScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: Business Energy and Industrial Strategy
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for Business Energy and Industrial Strategy. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
2.1Bids / Report
64% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 26 active published awards; 25 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityBusiness Energy and Industrial Strategy
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published1 Apr 2021, 18:14 BST
Last source update1 Apr 2021, 18:14 BST
Recurring procurementNot published
ClassificationPharmaceutical products
Delivery area
Wales (UKL)
OCIDocds-h6vhtk-02a25c
What is being bought
Procurement for REGN-COV2.
What changed
From the official release history
  1. Status changed to complete
    1 Apr 2021, 18:14 BST
  2. Official notice release published
    1 Apr 2021, 18:14 BST
  3. Buyer information updated
    1 Apr 2021, 18:14 BST
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    cancelled
    Published valueNot published
    Procurement for REGN-COV2. Additional information: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors and (iii) impact fair competition between vendors .
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    1 Apr 2021, 18:14 BST
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 5 Mar 2021, 00:00 GMT · £1
Commercial outcome and competition
Awards
Roche Products Limited
Not published · Not published · active
Contracts
REGN-COV2 SUPPLY AGREEMENT FOR PANDEMIC PURPOSES
£1 · signed 5 Mar 2021, 00:00 GMT · active
Bid statistics
bids: 1 (lot 1)
Buyer and organisations in this procedure

Business Energy and Industrial Strategy

Contracting authority GB-FTS-5606
View buyer profile

  • Business Energy and Industrial Strategy
    buyer

    1 Victoria Street, London, UK, SW1H0ET
    VTFContracts@beis.gov.uk

  • Department of Business, Energy and Industrial Strategy
    reviewBody

    London

  • Roche Products Limited
    supplier

    Welwyn Garden City, UKL
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleOur position, after reviewing the advice from counsel, is that under the unforeseen current global public health crisis there is a strong argument that the direct award of a contract with Roche is compliant with current PCR regulations in respect to section 32(2)(c). Firstly, the urgent award to Roche is strictly necessary to prevent significant loss of life, disease, and protracted periods of continued economic stress. Delay in acquiring binding assurances to reserves of antibody doses would pose an imminent risk for long term procurement of a antibody to combat the Covid-19 pandemic. Therefore, the UKs adoption of a protectionist approach to acquiring the Regeneron antibody via a direct award is fully justified under PCR regulation 32(2)(c).